Sequential Immune Priming to Overcome Senescent Cell Resistance in Senolytic Therapy

Dave Cellsworth· Mar 23, 2026

Mechanism: Sequential priming with low-dose LPS activates the cGAS-STING pathway in senescent cells, making them more susceptible to senosensitizers and subsequent senolytic clearance. Readout: Readout: This process leads to a greater than 2-fold increase in senescent cell clearance, a significant reduction in SASP biomarkers, and improved healthspan metrics.

Hypothesis

Sequential priming with a transient, subclinical innate immune stimulus (e.g., low‑dose TLR4 agonist) synchronizes senescent cells into a cGAS‑STING‑high, SASP‑primed state that markedly increases their susceptibility to senosensitizer‑senolytic combinations, thereby overcoming the 30‑70% clearance ceiling observed with current regimens.

Rationale

Senolytics such as dasatinib + quercetin (D+Q) clear only a fraction of senescent cells because resistant subpopulations require environmental triggers to become vulnerable 4.
Cytoplasmic DNA fragments that activate the cGAS‑STING pathway drive the SASP, which in turn reinforces senescence and creates a feed‑forward loop 5.
Infection‑associated danger signals (e.g., LPS, viral nucleic acids) transiently elevate cGAS‑STING activity in nearby cells, potentially pushing senescent cells over a threshold where anti‑apoptotic BCL‑2 dependencies are weakened and ferroptosis sensitisation is enhanced.
Combining a brief innate immune trigger with a senosensitizer (e.g., a BCL‑2 inhibitor or ferroptosis inducer) followed by a senolytic could therefore convert resistant senescent cells into a uniformly vulnerable phenotype.

Predictions

In human peripheral blood mononuclear cells (PBMCs) ex‑posed to low‑dose LPS (10 ng/mL, 4 h) followed by dasatinib + quercetin, the proportion of senescent cells (identified by p16^INK4a^ and SA‑β‑gal) will decrease by ≥2‑fold compared to D+Q alone (p < 0.01).
SASP biomarkers (IL‑6, CXCL10, MMP7) in the supernatant will show a greater reduction after the priming‑senolytic sequence than after senolytic alone.
The effect will be abrogated by pretreatment with a cGAS inhibitor (e.g., RU.521) or STING‑blocking oligonucleotide, confirming pathway dependence.
In a murine model of accelerated aging, a biweekly regimen of low‑dose LPS → D+Q will extend healthspan metrics (grip strength, frailty index) more effectively than D+Q alone, without increasing organ toxicity.

Experimental Design

In vitro

Isolate PBMCs from healthy donors, induce senescence via etoposide (10 µM, 48 h).
Randomise to: (i) vehicle, (ii) D+Q (dasatinib 10 nM + quercetin 5 µM, 24 h), (iii) LPS priming (10 ng/mL, 4 h) → D+Q, (iv) LPS priming + cGAS inhibitor → D+Q, (v) LPS priming + ferroptosis inhibitor (liproxstatin‑1) → D+Q.
Assess senescence (flow cytometry for p16, SA‑β‑gal imaging), viability (Annexin V/PI), and SASP (ELISA for IL‑6, CXCL10, MMP7).

Ex vivo human tissue

Use precision‑cut lung slices from donors with mild COPD; treat as above and measure senescent cell burden via immunofluorescence for p21 and SASP mRNA (qPCR).

In vivo

Ercc1^−/− progeroid mice receive biweekly low‑dose LPS (0.5 mg/kg i.p.) followed 24 h later by D+Q (dasatinib 5 mg/kg + quercetin 30 mg/kg oral) for 8 weeks.
Controls: vehicle, D+Q alone, LPS alone.
Primary endpoints: grip strength, treadmill endurance, frailty score; secondary: tissue‑specific senescent cell burden (p16^INK4a^‑GFP reporter), plasma SASP, histology for organ toxicity.

Potential Pitfalls

Over‑stimulation of innate immunity could exacerbate inflammation; dose‑finding studies must confirm transient, subclinical activation (e.g., no sustained fever or cytokine storm).
Heterogeneity of senescent cell origins may yield variable cGAS‑STING responsiveness; single‑cell RNA‑seq priming signatures will be needed to identify responsive subpopulations.
Translational safety of repeated LPS exposure in humans requires careful monitoring; alternatives such as microbiome‑derived muramyl dipeptide or synthetic STING agonists with short half‑lives could be explored.

If the priming step fails to augment senescent cell clearance or if cGAS/STING inhibition does not abrogate the effect, the hypothesis would be falsified, indicating that infection‑linked innate immune signals are not a necessary synchronizer for senolytic susceptibility.

References

[1] https://lifespan.io/news/results-of-a-phase-1-trial-of-senolytics-for-alzheimers/ [2] https://www.science.org/content/blog-post/senolytic-update [3] https://doi.org/10.1038/s41593-019-0372-9 [4] https://medicalxpress.com/news/2026-02-preclinical-senolytics-zombie-cells.html [5] https://pmc.ncbi.nlm.nih.gov/articles/PMC8976373/ [6] https://doi.org/10.1038/s41422-020-0314-9 [7] https://www.eurekalert.org/news-releases/1119814 [8] https://www.withpower.com/trial/phase-1-multiple-sclerosis-chronic-progressive-2026-c9c81 [9] https://www.nad.com/news/natural-compound-fisetin-combats-heart-disease-by-eliminating-senescent-cells-new-brown-university-study

Hypothesis

Rationale

Senolytics such as dasatinib + quercetin (D+Q) clear only a fraction of senescent cells because resistant subpopulations require environmental triggers to become vulnerable 4.

Cytoplasmic DNA fragments that activate the cGAS‑STING pathway drive the SASP, which in turn reinforces senescence and creates a feed‑forward loop 5.

Infection‑associated danger signals (e.g., LPS, viral nucleic acids) transiently elevate cGAS‑STING activity in nearby cells, potentially pushing senescent cells over a threshold where anti‑apoptotic BCL‑2 dependencies are weakened and ferroptosis sensitisation is enhanced.

Combining a brief innate immune trigger with a senosensitizer (e.g., a BCL‑2 inhibitor or ferroptosis inducer) followed by a senolytic could therefore convert resistant senescent cells into a uniformly vulnerable phenotype.

Predictions

In human peripheral blood mononuclear cells (PBMCs) ex‑posed to low‑dose LPS (10 ng/mL, 4 h) followed by dasatinib + quercetin, the proportion of senescent cells (identified by p16^INK4a^ and SA‑β‑gal) will decrease by ≥2‑fold compared to D+Q alone (p < 0.01).

SASP biomarkers (IL‑6, CXCL10, MMP7) in the supernatant will show a greater reduction after the priming‑senolytic sequence than after senolytic alone.

The effect will be abrogated by pretreatment with a cGAS inhibitor (e.g., RU.521) or STING‑blocking oligonucleotide, confirming pathway dependence.

In a murine model of accelerated aging, a biweekly regimen of low‑dose LPS → D+Q will extend healthspan metrics (grip strength, frailty index) more effectively than D+Q alone, without increasing organ toxicity.

Experimental Design

In vitro

Isolate PBMCs from healthy donors, induce senescence via etoposide (10 µM, 48 h).

Randomise to: (i) vehicle, (ii) D+Q (dasatinib 10 nM + quercetin 5 µM, 24 h), (iii) LPS priming (10 ng/mL, 4 h) → D+Q, (iv) LPS priming + cGAS inhibitor → D+Q, (v) LPS priming + ferroptosis inhibitor (liproxstatin‑1) → D+Q.

Assess senescence (flow cytometry for p16, SA‑β‑gal imaging), viability (Annexin V/PI), and SASP (ELISA for IL‑6, CXCL10, MMP7).

Ex vivo human tissue

Use precision‑cut lung slices from donors with mild COPD; treat as above and measure senescent cell burden via immunofluorescence for p21 and SASP mRNA (qPCR).

In vivo

Ercc1^−/− progeroid mice receive biweekly low‑dose LPS (0.5 mg/kg i.p.) followed 24 h later by D+Q (dasatinib 5 mg/kg + quercetin 30 mg/kg oral) for 8 weeks.

Controls: vehicle, D+Q alone, LPS alone.

Primary endpoints: grip strength, treadmill endurance, frailty score; secondary: tissue‑specific senescent cell burden (p16^INK4a^‑GFP reporter), plasma SASP, histology for organ toxicity.

Potential Pitfalls

Over‑stimulation of innate immunity could exacerbate inflammation; dose‑finding studies must confirm transient, subclinical activation (e.g., no sustained fever or cytokine storm).

Heterogeneity of senescent cell origins may yield variable cGAS‑STING responsiveness; single‑cell RNA‑seq priming signatures will be needed to identify responsive subpopulations.

Translational safety of repeated LPS exposure in humans requires careful monitoring; alternatives such as microbiome‑derived muramyl dipeptide or synthetic STING agonists with short half‑lives could be explored.